The proposed, Finnish, ProScreen trial

A group of Finnish researchers have planned a new trial to investigate whether population-based screening for prostate cancer is justifiable if a mortality benefit can be proven with a substantial reduction in rates of over-treatment. … READ MORE …

“Discussing overdiagnosis is good science”

The term “over-diagnosis” didn’t exist 15 years ago in the management of prostate cancer. (Well, actually it did, but it would very rarely — if ever — have come to the notice of any patient or even of the average urologist or primary care physician.) … READ MORE …

The “right” ways to treat TxN1M0 disease today

Really sound guidance on “the best” way to treat men who are initially diagnosed with lymph node-positive (TxN1M0) prostate cancer — or are found to have such cancer at the time of first-line surgery — is not as readily available as one might like. … READ MORE …

Gallium-68 PSMA PET/CT scans changed management in 39 percent of patients

The gold standard for the clinical relevance of any new test in the management of a specific disease is … Do the results of the test change the way a physician would previously have managed patients? … READ MORE …

“Active surveillance … how to do it right”

Many readers, and particularly many support group leaders and other educators, may want to read and retain a copy of this very recent article in Oncology. … READ MORE …

Active surveillance in men with higher-risk forms of localized prostate cancer

The abstract of a paper currently in press in the Journal of Urology has offered us some potentially fascinating insight into the comparative outcomes of patients with low- and higher-risk forms of localized prostate cancer when they are initially managed on active surveillance. … READ MORE …

Informing the media community about prostate cancer and its management

A new article on the HealthNewsReview web site addresses issues related to the diagnosis of prostate cancer and the management of low-risk forms of the disease using active surveillance. … READ MORE …